A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
about
Vortioxetine for depression in adultsDuloxetine versus other anti-depressive agents for depressionVortioxetineCognitive remission: a novel objective for the treatment of major depression?The role of cognitive dysfunction in the symptoms and remission from depressionEffects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell functionProfile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literatureThe Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsInfluence of Pharmacotherapy on Cognitive Functions in Depression: A Review of the LiteratureThe safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.Chronic Vortioxetine Treatment Reduces Exaggerated Expression of Conditioned Fear Memory and Restores Active Coping Behavior in Chronically Stressed RatsPharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder.A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agUnder the Influence: The Interplay among Industry, Publishing, and Drug Regulation.Major depressive disorder and cognitive impairmentA randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression.The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus.Vortioxetine: a New Treatment for Major Depressive Disorder.Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension studyMultimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats.Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters.Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine.Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment.Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis.The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trialsMajor depressive disorder: mechanism-based prescribing for personalized medicineDepression and cerebrovascular disease: could vortioxetine represent a valid treatment option?Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorderA randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.Diagnosis and treatment of depression and cognitive impairment in late life.A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive DisorderBehavioral Health and Primary Care: A Status ReportCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsThe Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.
P2860
Q24186313-71EB5298-E3E2-4C32-80BD-19F47DBF5962Q24198808-86F39F9B-3614-4457-8D91-4DD431A63584Q26773284-454BB5E9-0B24-4257-B4C7-9FA236B20B78Q26775386-2067F97A-CE52-4D0E-8C77-A408EC9A81BEQ26781910-7EC041AA-068F-48C5-A63C-1DFBF5585A2EQ26783101-F7C6EDBD-A621-4E06-A956-372B1D97DB32Q26796436-B621DFE9-1F30-4058-BE6B-28E0B73C97DBQ26799627-FF2F03D7-A58F-41AE-8F63-90D2CE074ABFQ27694555-725CF729-D2DB-43A9-9AF8-AF04F8AC2586Q31044175-4785909C-6CDB-4391-9177-E7C998FE680DQ33614804-78B2B1E1-E329-439A-99C1-75D957B7C9C8Q33933912-1E137427-B99D-4704-B1AD-DA4F2FA2FA56Q34033547-59C3B77F-FD88-4877-9981-69395BDB0A26Q34041642-78DD1F75-4797-4501-8EB5-9436DEEECAE3Q34046215-1498CA77-9762-4A84-8A73-E2A510AB8641Q34160814-9310E816-88BA-4B82-8E41-E44F416A5C61Q34172150-053FDFAB-5CC6-4C88-ACCF-600F818DF99BQ34335586-7CC2976F-5C66-4DB0-AE63-A3546CFC1E66Q34497909-CA104D8D-96B4-4870-80C4-27DE803112B7Q34505291-35F73369-61D3-48B4-9657-9B180E73BDEDQ34505568-A3E98834-E635-4464-B1F7-34B2BCD0C6EBQ34531545-48D17F63-6F99-4196-923E-667056FFE5F8Q34559591-9061586B-72F2-435A-A2FA-78ACF64723B8Q34670569-7910BE5B-F438-4739-811F-27A4402CA34EQ34671039-670CFB67-A2D6-44A5-8C75-11F95908F899Q35006371-BAD6D9AB-AA4D-4411-A4BC-3D9D620AC593Q35066804-026189FD-002B-481A-A03A-FD95DF6600C1Q35154113-B2165AEB-62A5-4795-93AE-48351B4C6E1BQ35280477-23E7472A-F7D5-495C-83D9-C53B80175189Q35284412-3A465807-AFE9-4614-924C-969365A08AAEQ35426685-A8CC07A8-2433-42B8-BC3A-155218A280DCQ35536869-6C390786-2D3B-4F9D-9D6C-5F51946A56D9Q35607556-3495F945-A45F-4562-B96C-C0E25EDA6A92Q35660942-1B7E325B-8653-4DB8-BA0A-309735D2D1ADQ36821817-9BF75BD4-57CA-4290-9DD5-1B8DDE689566Q36921847-C660A087-CDED-42D0-94D3-644AEF978094Q37197207-491CA737-A3BF-420B-BF21-7679E13A9A2AQ37197216-39277774-F5C4-445D-B8C8-5B5BD1B52D1BQ37388486-FC70647F-ED07-4883-90B6-C23448AA13F5Q37601281-90880493-EE0F-48F8-BBA1-C170BB45BF7F
P2860
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A randomized, double-blind, pl ...... ith major depressive disorder.
@ast
A randomized, double-blind, pl ...... ith major depressive disorder.
@en
A randomized, double-blind, pl ...... ith major depressive disorder.
@nl
type
label
A randomized, double-blind, pl ...... ith major depressive disorder.
@ast
A randomized, double-blind, pl ...... ith major depressive disorder.
@en
A randomized, double-blind, pl ...... ith major depressive disorder.
@nl
prefLabel
A randomized, double-blind, pl ...... ith major depressive disorder.
@ast
A randomized, double-blind, pl ...... ith major depressive disorder.
@en
A randomized, double-blind, pl ...... ith major depressive disorder.
@nl
P2093
P921
P1476
A randomized, double-blind, pl ...... ith major depressive disorder.
@en
P2093
Christina Kurre Olsen
Cornelius Katona
Thomas Hansen
P304
P356
10.1097/YIC.0B013E3283542457
P577
2012-07-01T00:00:00Z